Augmented behavioral response and enhanced synaptosomal calcium transport induced by repeated cocaine administration are decreased by calcium channel blockers.
Recent studies suggest that calcium influx via L-type calcium channels is necessary for psychostimulant-induced behavioral sensitization. In addition, chronic amphetamine upregulates subtype Cav1.2-containing L-type calcium channels. In the present studies, we assessed the effect of calcium channel blockers (CCBs) on cocaine-induced behavioral sensitization and determined whether the functional activity of L-type calcium channels is altered after repeated cocaine administration. Rats were administered daily intraperitoneal injections of either flunarizine (40 mg/kg), diltiazem (40 mg/kg) or cocaine (20 mg/kg) and the combination of the CCBs and cocaine for 30 days. Motor activities were monitored on Day 1, and every 6th day during the 30-day treatment period. Daily cocaine administration produced increased locomotor activity. Maximal augmentation of behavioral response to repeated cocaine administration was observed on Day 18. Flunarizine pretreatment abolished the augmented behavioral response to repeated cocaine administration while diltiazem was less effective. Measurement of tissue monoamine levels on Day 18 revealed cocaine-induced increases in DA and 5-HT in the nucleus accumbens. By contrast to behavioral response, diltiazem was more effective in attenuating increases in monoamine levels than flunarizine. Cocaine administration for 18 days produced increases in calcium uptake in synaptosomes prepared from the nucleus accumbens and frontal cortex. Increases in calcium uptake were abolished by flunarizine and diltiazem pretreatment. Taken together, the augmented cocaine-induced behavioral response on Day 18 may be due to increased calcium uptake in the nucleus accumbens leading to increased dopamine (DA) and serotonin (5-HT) release. Flunarizine and diltiazem attenuated the behavioral response by decreasing calcium uptake and decreasing neurochemical release.
Mills
K
K
Department of Pharmacology, Meharry Medical College, Nashville, TN 37208, USA.
Ansah
T A
TA
Ali
S F
SF
Mukherjee
S
S
Shockley
D C
DC
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D015306:Biogenic Monoamines / Q000378:metabolism; D001693:Biological Transport, Active; D002118:Calcium / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D020746:Calcium Channels, L-Type / Q000187:drug effects / Q000502:physiology; D002132:Calcium Radioisotopes; D002421:Caudate Nucleus / Q000187:drug effects / Q000378:metabolism; D003042:Cocaine / Q000037:antagonists & inhibitors* / Q000494:pharmacology*; D004110:Diltiazem / Q000494:pharmacology; D005444:Flunarizine / Q000494:pharmacology; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism; D017397:Prefrontal Cortex / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013574:Synaptosomes / Q000187:drug effects / Q000378:metabolism*
D015306:Biogenic Monoamines; D002121:Calcium Channel Blockers; D020746:Calcium Channels, L-Type; D002132:Calcium Radioisotopes; D004110:Diltiazem; D003042:Cocaine; D005444:Flunarizine; D002118:Calcium
Neuropsychopharmacology. 1999 Jun;20(6):591-602
10327428
Brain Res. 1999 Jul 3;833(2):133-41
10375688
Eur J Pharmacol. 1999 Jul 9;376(3):207-15
10448878
Psychopharmacology (Berl). 2000 Sep;152(1):110-8
11041323
Addiction. 2001 Jan;96(1):103-14
11177523
Psychopharmacology (Berl). 2001 May;155(3):221-9
11432683
J Neurochem. 2002 Apr;81(2):292-300
12064476
Annu Rev Psychol. 2003;54:25-53
12185211
Pharmacol Biochem Behav. 2002 Nov;73(4):877-82
12213534
J Neurochem. 2003 Apr;85(1):14-22
12641723
Neurochem Int. 1992 Jul;21(1):99-107
1303146
Cell Calcium. 1992 Nov;13(10):659-67
1337502
Pharmacol Biochem Behav. 1992 Dec;43(4):1023-31
1361988
J Neurosci. 2003 Nov 12;23(32):10265-73
14614085
J Biol Chem. 1951 Nov;193(1):265-75
14907713
J Neurosci. 2004 Aug 25;24(34):7464-76
15329393
Pharmacol Biochem Behav. 1992 Mar;41(3):497-500
1533936
Life Sci. 2006 Aug 1;79(10):981-90
16765386
Brain Res Bull. 1991 Mar;26(3):445-7
1828708
Life Sci. 1991;49(2):165-70
2062172
Eur J Pharmacol. 1990 Nov 6;190(1-2):217-21
2076753
Eur J Pharmacol. 1990 Nov 6;190(1-2):223-7
2076754
Circ Res. 1990 Aug;67(2):469-80
2165445
Life Sci. 1990;46(9):635-45
2308472
Eur J Pharmacol. 1990 Feb 6;176(2):245-6
2311670
J Physiol. 1975 Jun;247(3):617-55
238033
Biochem Pharmacol. 1986 Jul 1;35(13):2193-7
2425811
Biochemistry. 1988 Jul 12;27(14):5275-81
2458759
Eur J Pharmacol. 1989 Jul 18;166(2):261-9
2477260
J Neurosci. 1985 Mar;5(3):841-9
2579220
Ann N Y Acad Sci. 1998 May;844(1):201-207
29090812
Brain Res. 1985 Mar 25;330(2):217-23
2985193
Brain Res. 1981 Dec 7;226(1-2):107-18
7296283
J Neurosci. 1995 Sep;15(9):6287-99
7666211
J Pharmacol Exp Ther. 1995 Feb;272(2):791-8
7853196
Psychopharmacology (Berl). 1994 Jan;113(3-4):378-80
7862848
Psychopharmacology (Berl). 1994 Jan;113(3-4):404-10
7862852
Life Sci. 1995;56(7):475-83
7869827
Pharmacol Biochem Behav. 1994 Apr;47(4):973-9
8029272
Pharmacol Biochem Behav. 1993 Mar;44(3):661-4
8095726
Life Sci. 1993;53(26):1947-56
8255157
Pharmacol Biochem Behav. 1993 Nov;46(3):715-22
8278450
Mol Neurobiol. 1995 Aug-Dec;11(1-3):31-46
8561966
J Physiol Pharmacol. 1996 Sep;47(3):497-502
8877905
Physiol Behav. 1996 Nov;60(5):1261-7
8916180
Brain Res. 1996 Oct 21;737(1-2):215-20
8930368
Life Sci. 1997;60(8):PL119-26
9042392
J Neurosci. 1997 May 1;17(9):3254-61
9096158
J Pharmacol Exp Ther. 1997 Aug;282(2):521-7
9262311
Pharmacol Biochem Behav. 1997 Dec;58(4):1117-22
9408222
Pharmacology. 1997 Dec;55(6):292-8
9413858
Nature. 1976 Apr 22;260(5553):731-2
944382
J Pharmacol Exp Ther. 1998 Apr;285(1):277-84
9536022
Eur J Pharmacol. 1998 Jan 26;342(2-3):339-45
9548406
J Psychopharmacol. 1998;12(1):49-53
9584968
Synapse. 1998 Jun;29(2):148-61
9593105
Am J Psychiatry. 1998 Jun;155(6):832-4
9619159
Drug Alcohol Depend. 1998 Jun-Jul;51(1-2):87-96
9716932
Pharmacol Biochem Behav. 1998 Oct;61(2):181-92
9738534